CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on chimeric antigen receptor T-cell therapies for the treatment of cancer, formed through the business combination of blank-check company Phoenix Biotech Acquisition Corp and privately held CERo Therapeutics. Phoenix Biotech Acquisition Corp, sponsored by Phoenix Biotech Sponsor LLC, completed its initial public offering in 2021 targeting the biotechnology and life sciences sector. The de-SPAC transaction closed in early 2023, and the combined company filed its inaugural 10-K annual report with the SEC on March 24, 2023, marking its first full disclosure period as a publicly traded oncology-focused entity. Investors and analysts seeking comprehensive SPAC deal data, filing timelines, and sponsor analytics can sign up for full access at SpacDesk.